Strand Therapeutics Exposes U.S. Innovation Crisis in Biotech

Strand Therapeutics isn’t just developing a new cancer treatment -- it’s exposing a broken system that delays life-saving medicine while competitors in China race ahead. The hidden consequence? Breakthroughs aren’t failing due to science, but because regulatory inertia creates a self-inflicted innovation gap. This conversation reveals how one company’s technical mission collided with policy failure, and how reframing the problem -- not just the drug -- accelerated change from op-ed to presidential policy in under two months. Executives, investors, and policymakers should read this because it maps a rare real-world case where systems thinking didn’t just diagnose dysfunction -- it triggered a cascade of high-level action. The advantage lies in seeing that technical ambition and policy reform aren’t separate tracks, but interdependent layers of the same race.

Why the Obvious Fix -- Better Drugs -- Isn’t Enough

Most biotech narratives focus on the molecule: the novel mechanism, the clinical response, the next-gen platform. But Jake Becraft’s story with Strand Therapeutics flips that script. The real bottleneck isn’t discovery -- it’s delivery, not of the drug, but of the entire innovation lifecycle. The image that stunned investors -- a melanoma patient with visceral metastases vanishing after treatment -- wasn’t just proof of concept. It was a provocation. A single patient’s scan became a mirror held up to an industry that celebrates scientific wins while ignoring systemic decay.

"We are the first company that I’m aware of to show this extent of abscopal response in visceral deep organ metastases in a multitude of patients."

-- Jake Becraft

That abscopal effect -- where injecting one tumor triggers systemic immune attack on distant, untreated tumors -- had been observed before. But only in localized skin lesions. Strand’s data showed regression in lung, muscle, and bone -- the very sites that kill. That’s the scientific breakthrough. But Becraft didn’t stop there. He asked: Why hasn’t this scaled? The answer wasn’t biological. It was structural. The drug worked. The system didn’t.

Because even if your drug can reprogram cancer cells to scream for immune destruction, none of it matters if patients can’t access it. And access isn’t just about cost -- it’s about infrastructure. Most oncology treatments are delivered via IV infusion in outpatient clinics. But Strand’s first therapy required direct tumor injection -- feasible for skin lesions, impractical for deep organ disease, and impossible in rural or under-resourced settings. The drug was a success. The product wasn’t.

This is where conventional biotech thinking fails. It assumes that efficacy equals impact. But Becraft saw the second-order consequence: a therapy confined to major academic centers becomes a boutique solution, not a revolution. The immediate win -- tumor regression -- masked the downstream failure -- inequitable access. His insight? Fix the delivery system, not just the payload. That’s why Strand’s real mission isn’t one drug. It’s building a platform to deliver genetic instructions anywhere in the body -- starting with IV-administered RNA therapies.

The 30-Year Bottleneck No One Wants to Fix

For decades, genetic medicine has been trapped in the liver. Why? Because when you inject RNA into the bloodstream, the liver filters it out. That’s not a flaw -- it’s biology. But it became a ceiling. The industry’s response? Optimize for the liver. Treat liver diseases. Celebrate incremental gains. The deeper problem -- how do we get genetic medicines to other organs? -- was hand-waved as a “delivery problem.” Simple. Solvable. Just fix the vector.

Becraft calls that thinking lazy.

"Everyone who thinks they know what they’re talking about in genetic medicine will say well the issue is delivery and it's like you need to be able to deliver and I'm like that's a very hand wavy... it's just a cheap answer which is like not wrong but it is incomplete."

-- Jake Becraft

He reframes it as three problems in one: potency, specificity, and delivery -- “three children in their father’s trench coat.” You can’t solve one without the others. A delivery vehicle that reaches the lung but lacks potency fails. One that’s potent but not specific causes toxicity. One that’s specific but can’t be manufactured at scale never reaches patients.

This is systems thinking in action. Most companies optimize one variable. Strand is engineering the entire chain. And that reveals a deeper truth: the biggest barriers to progress aren’t scientific -- they’re institutional. The regulatory process, designed for small-molecule drugs, now chokes the very innovation it’s meant to enable.

The FDA’s Hidden Tax on Innovation

Here’s the hidden cost no one talks about: getting permission to test a drug in humans. In the U.S., launching a Phase 1 trial requires an Investigational New Drug (IND) application to the FDA. Becraft describes his first IND as 22,000 pages long. The cost? $25 million. The time? 18 months. All before a single human sees the drug.

Compare that to Australia or China, where companies can notify regulators and go straight to Institutional Review Boards (IRBs) at hospitals. The result? Faster trials, broader access, and a migration of innovation. U.S. biotechs, priced out of their own system, are running trials overseas. Then, Chinese companies use that same infrastructure to develop their drugs -- and bring them back to the U.S. for approval.

The system is cannibalizing itself.

Becraft’s insight isn’t just that reform is needed -- it’s that the U.S. is losing a strategic race. China isn’t just catching up. It’s industrializing clinical development. And the U.S. response -- layers of risk-averse bureaucracy -- is accelerating the shift.

So he proposed a radical alternative: a Clinical Trial Notification (CTN) system, like Australia’s. Let hospitals and IRBs -- the entities closest to patients -- make the go/no-go decision. Free the FDA to focus on drug approval, not trial permission. Distribute oversight. Build capacity. Let the market, not the regulator, decide where trials happen.

The immediate effect? Lower cost, faster timelines. The second-order effect? More Americans gain access to experimental therapies. Hospitals invest in trial infrastructure. Startups aren’t forced into elite academic centers. The innovation flywheel spins faster.

But here’s the kicker: this isn’t just about efficiency. It’s about national competitiveness. Biotech, like AI and semiconductors, is a strategic industry. And right now, the U.S. is outsourcing its future.

From Op-Ed to Oval Office: The Power of Framing

This is where most stories end -- with a smart idea stuck in a PowerPoint. But Becraft’s journey didn’t stop at diagnosis. He weaponized narrative.

His op-ed in The Washington Post, “The U.S. Can’t Afford to Offshore Clinical Trials to China,” didn’t just explain the problem. It framed it as a solvable crisis. Bad news: we’re falling behind. Good news: we can fix it. That’s not spin. It’s strategy.

Policymakers don’t respond to despair. They respond to agency. And Becraft gave them a lever: streamline first-in-human trials. Within weeks, the idea was picked up by congressional staff. Then hearings. Then, in a stunningly short window, it appeared in the President’s legislative priorities.

"Between the testimony and a number of meetings after that that day around D.C. we really started to form a sort of fervor... the president put out his policy objectives... and in those legislative objectives... is this exact idea of removing barriers to getting early stage experimental medicines to American patients."

-- Jake Becraft

That’s the 18-month payoff no one sees. The discomfort of challenging orthodoxy. The patience to reframe, test, and refine. The willingness to speak directly to power -- not with demands, but with solutions.

It also reveals a deeper truth about change: no one will learn until they care. Scientists want data. Policymakers want stories. Becraft learned to bridge that gap. Start with the patient. Then the platform. Then the policy. Make them care. Then they’ll listen.

The Platform Play: Biotech’s Domino’s Moment

Most biotechs are real estate developers: build one asset, sell it, move on. Becraft wants to build Domino’s -- a scalable infrastructure that can deliver any therapeutic payload, anywhere.

Moderna’s mRNA platform proved the concept: one technological base, multiple vaccines. Strand’s goal is similar but broader. Their RNA platform isn’t just for cancer. It’s for any disease where you need to reprogram cells -- autoimmune disorders, genetic diseases, regenerative medicine.

The first drug is a milestone. The platform is the moat.

But building it requires patient capital. And that’s where the U.S. innovation ecosystem falters. Venture capital rewards quick exits, not long-term platform building. The result? A pipeline of “single-shot” biotechs designed for acquisition, not impact.

Becraft’s model is different: post-conviction, pre-consensus. He’s not asking if the science works -- it does. He’s asking who believes in the long arc. Who will fund the infrastructure, not just the next molecule?

This is where the comparison to SpaceX and Amazon isn’t hype -- it’s a roadmap. Bezos didn’t build Amazon for quarterly profits. Musk didn’t build SpaceX for short-term returns. They built platforms. And they attracted investors who saw beyond the next milestone.

Becraft is doing the same. But he’s doing it in an industry that still thinks in silos. The advantage? While others optimize for the next funding round, Strand is building for the next decade.

Key Action Items

• Reframe innovation as a systems problem, not just a scientific one -- Over the next quarter, audit your product development process for hidden bottlenecks in delivery, access, or regulation. The biggest barrier may not be your technology, but the ecosystem around it.

• Prioritize platform thinking over single-product wins -- This pays off in 12--18 months. Shift R&D focus from isolated breakthroughs to reusable infrastructure. Ask: “Can this solution scale to multiple indications?” If not, redesign.

• Engage policymakers with solutions, not complaints -- Within six months, identify one regulatory or policy barrier slowing your work. Draft a concise, actionable proposal (like the CTN system) and share it with relevant stakeholders. Discomfort now prevents stagnation later.

• Test your messaging with real audiences before scaling -- Use split-testing (e.g., PickFu) on headlines, pitches, or policy briefs. The message that wins internally may not resonate externally. Optimize for engagement, not elegance.

• Seek capital aligned with long-term vision, not short-term milestones -- Over the next 12 months, target investors who understand platform value. Avoid partners incentivized by quick exits. This requires patience but creates durable advantage.

• Build for existing infrastructure, not idealized futures -- Design therapies, trials, and delivery systems that plug into current healthcare workflows. Disruption fails when it demands too much change too fast.

• Share your journey publicly -- Start a newsletter, publish updates, speak at events. Transparency attracts aligned partners and builds trust. The story of progress is as valuable as the progress itself.